Libuse Tauchmanova

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([131I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).

Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([131I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).

Journal: Neuro-oncology advances

Published: August 30, 2024

[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: May 24, 2024

Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.

Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.

Journal: Endocrine

Published: May 12, 2021

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

Journal: The lancet. Diabetes & endocrinology

Published: October 14, 2019

Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.

Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.

Journal: Journal of endocrinological investigation

Published: September 23, 2019

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.

Journal: European journal of endocrinology

Published: August 30, 2019

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.

Journal: Pituitary

Published: August 24, 2019

Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Journal: Clinical endocrinology

Published: June 27, 2019

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.

Journal: Cancer chemotherapy and pharmacology

Published: August 02, 2018

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Journal: The lancet. Diabetes & endocrinology

Published: May 04, 2017

Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells.

Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells.

Journal: TheScientificWorldJournal

Published: December 17, 2013

Accelerated bone mass senescence after hematopoietic stem cell transplantation.

Accelerated bone mass senescence after hematopoietic stem cell transplantation.

Journal: Translational medicine @ UniSa

Published: August 02, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026